Jeff is a deal lawyer with a broad transactional practice focused exclusively on the life sciences industry.
Jeff represents a wide range of clients—including multinational pharmaceutical companies, biotechs, private equity portfolio companies, and other players in the life sciences ecosystem—on their most strategic transactions, spanning complex licensing and collaboration and M&A matters. He also frequently advises on operational agreements such as supply, distribution, research, and IP license agreements, both on a standalone basis and in the context of larger deals.
Jeff began his career as a patent litigator and regularly leverages his substantive IP experience in his practice. He also previously worked in Freshfields’ London office.
Licensing & Collaboration Transactions
- Novartis on its (i) strategic collaboration with Vyriad regarding the discovery and development of in vivo chimeric antigen receptor (CAR) T-cell therapies, (ii) co-development and co-commercialization agreement with UCB regarding disease-modifying therapies for Parkinson’s Disease, (iii) collaboration with Cellular Biomedicine Group regarding the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China, (iv) collaboration with Mesoblast regarding remestemcel-L for the treatment of acute respiratory distress syndrome, and (v) collaboration with Sangamo Therapeutics regarding gene regulation therapies directed to neurodevelopmental targets.
- SERB Pharmaceuticals on its license from SFJ Pharmaceuticals to obtain exclusive U.S. rights to bentracimab, a ticagrelor reversal agent.
- Camurus on its collaboration with Eli Lilly for the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology.
- Moderna on its collaboration with CARsgen Therapeutics for the development of a combination therapy consisting of an mRNA-based cancer vaccine and an autologous CAR-T therapy.
- Capsida Biotherapeutics on its collaboration with Prevail Therapeutics regarding CNS gene therapies.
- Spark Therapeutics on its collaboration with Senti Biosciences regarding gene therapies directed to specific cell types in the central nervous system, eye, and liver.
- Gilead Sciences on its (i) collaboration with Agenus regarding novel immuno-oncology therapies, (ii) collaboration with Hookipa Biotech regarding immunotherapies directed against hepatitis B virus and human immunodeficiency virus, (iii) collaboration with Tango Therapeutics regarding cancer immunotherapies, and (iv) license with Xencor regarding effector-enhanced, broadly neutralizing anti-HIV antibodies.
- Celgene on the restructuring of its collaboration with Jounce Therapeutics regarding immuno-oncology therapies.
M&A Transactions
- Novartis on its acquisitions of AveXis, Cadent Therapeutics, IFM Tre, MorphoSys AG, and Vedere Bio, as well as its option to acquire (and collaboration with) IFM Due.
- AstraZeneca on its acquisition of Gracell Biotechnologies.
- Roivant Sciences on its $7.1 billion sale of Telavant to Roche and its sale of Dermavant to Organon for up to $1.2 billion.
- SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc.
- Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism of action to treat invasive mold infections.
- Convatec Group on its acquisition of an innovative antimicrobial nitric oxide platform from 30 Technology.
- Recordati, a portfolio company of CVC Capital Partners, on its acquisition of EUSA Pharma (UK) Limited.
- Celgene on its acquisition of Juno Therapeutics.
- Kite Pharma, a Gilead company, on its option to acquire, and related strategic collaboration with, Gadeta B.V.
- Bausch Health on its option to acquire certain assets of Allegro Ophthalmics.
- Jazz Pharmaceuticals on its acquisition of Cavion.
3 World Trade Center
175 Greenwich Street, 51st Floor